{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:00:15Z","timestamp":1792252815327,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Polyethylene glycol (PEG) has been widely utilized in optimizing therapeutics due to its excellent biocompatibility and chemical stability. However, multiple dosing of PEGylated drugs may result in toxicity due to PEG accumulation in tissues, leading to the formation of anti-PEG antibodies (APAs), which can accelerate drug clearance, reduce efficacy, and alongside enhanced side effects, such as allergic reactions. Notably, pre-existing APAs have also been detected in individuals with no prior exposure to PEGylated drugs, raising additional clinical concerns. This review summarizes the mechanisms of APA generation, the factors influencing PEG immunogenicity, and the biological consequences of APAs on drug pharmacokinetics, efficacy, and safety. We also discuss current challenges in APA detection and highlight strategies to minimize immunogenic responses, including PEG modification, immunomodulation, and alternative polymers. This review aims to provide a comprehensive reference for the rational design, evaluation, and clinical management of PEGylated drugs.<\/jats:p>","DOI":"10.3390\/pharmaceutics17081074","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:18:14Z","timestamp":1755695894000},"page":"1074","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization"],"prefix":"10.3390","volume":"17","author":[{"given":"Shujun","family":"Fu","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation, Chinese National Medical Product Administration, Beijing 100076, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueran","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghua","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation, Chinese National Medical Product Administration, Beijing 100076, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2021.12.030","article-title":"Evolution of drug delivery systems: From 1950 to 2020 and beyond","volume":"342","author":"Park","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","article-title":"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.xphs.2023.11.001","article-title":"Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives","volume":"113","author":"Gaballa","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-409X(02)00180-1","article-title":"Effective drug delivery by PEGylated drug conjugates","volume":"55","author":"Greenwald","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0169-409X(95)00023-Z","article-title":"Chemistry of Polyethylene-Glycol Conjugates with Biologically-Active Molecules","volume":"16","author":"Zalipsky","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1517\/17425255.2014.967679","article-title":"Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns","volume":"10","author":"Zhang","year":"2014","journal-title":"Expert. Opin. Drug Met."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2005.05.016","article-title":"International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C","volume":"43","author":"Zeuzem","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin-Review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kong, Y.W., and Dreaden, E.C. (2022). PEG: Will It Come Back to You? Polyethelyne Glycol Immunogenicity, COVID Vaccines, and the Case for New PEG Derivatives and Alternatives. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.879988"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e26873","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated asparaginase, pegcrisantaspase: A report from the Children\u2019s Oncology Group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_18","first-page":"103","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer-Am. Cancer Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene-Glycol Reactive Antibodies in Man-Titer Distribution in Allergic Patients Treated with Monomethoxy Polyethylene-Glycol Modified Allergens or Placebo, and in Healthy Blood-Donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.immuni.2013.02.023","article-title":"Endocytosis and Recycling of Immune Complexes by Follicular Dendritic Cells Enhances B Cell Antigen Binding and Activation","volume":"38","author":"Heesters","year":"2013","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ni.2511","article-title":"Innate B cell helpers reveal novel types of antibody responses","volume":"14","author":"Vinuesa","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","first-page":"72","article-title":"State of the art in PEGylation: The great versatility achieved after forty years of research","volume":"64","author":"Pasut","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2012.07.049","article-title":"Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs","volume":"436","author":"Suzuki","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/acs.molpharmaceut.0c00366","article-title":"Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice","volume":"17","author":"Elsadek","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2020.04.026","article-title":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","volume":"152","author":"Elsadek","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejps.2016.06.007","article-title":"Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice","volume":"91","author":"Poppenborg","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)29419-2","article-title":"Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection","volume":"298","author":"Laverman","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","first-page":"455","article-title":"Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes","volume":"14","author":"Lai","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejpb.2012.04.023","article-title":"A frustrating problem: Accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats","volume":"81","author":"Zhao","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","volume":"172","author":"Kiwada","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","article-title":"Questioning the use of PEGylation for drug delivery","volume":"3","author":"Verhoef","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: A review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1016\/j.vaccine.2023.05.029","article-title":"Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination","volume":"41","author":"Zhou","year":"2023","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11357-021-00495-y","article-title":"A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: Complement activation as a possible contributing factor","volume":"44","author":"Kozma","year":"2022","journal-title":"Geroscience"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against Polyethylene-Glycol Produced in Animals by Immunization with Monomethoxy Polyethylene-Glycol Modified Proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"ref_46","first-page":"376","article-title":"Anaphylaxis to Pegylated Liposomal Doxorubicin: A Case Report","volume":"63","author":"Sharma","year":"2014","journal-title":"West Indian. Med. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","article-title":"Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients","volume":"363","author":"Miao","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.1021\/acsnano.3c11165","article-title":"Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine","volume":"18","author":"Shen","year":"2024","journal-title":"ACS Nano"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41467-024-50568-7","article-title":"Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin","volume":"15","author":"Jiang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"119792","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1208\/s12248-015-9799-4","article-title":"Development of a Generic Anti-PEG Antibody Assay Using BioScale\u2019s Acoustic Membrane MicroParticle Technology","volume":"17","author":"Dong","year":"2015","journal-title":"AAPS J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpba.2005.04.045","article-title":"Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies","volume":"39","author":"Geng","year":"2005","journal-title":"J. Pharm. Biomed."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","article-title":"Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective","volume":"21","author":"Findlay","year":"2000","journal-title":"J. Pharm. Biomed."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/acs.analchem.7b02447","article-title":"Sensitive and Quantitative Detection of Anti-Poly(ethylene glycol) (PEG) Antibodies by Methoxy-PEG-Coated Surface Plasmon Resonance Sensors","volume":"89","author":"Zhang","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4155\/bio.15.36","article-title":"Anti-PEG antibody bioanalysis: A clinical case study with PEG-IFN-\u03bb-1a and PEG-IFN-\u03b12a in naive patients","volume":"7","author":"Myler","year":"2015","journal-title":"Bioanalysis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2008.05.009","article-title":"Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives","volume":"130","author":"Xu","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.nantod.2024.102163","article-title":"Anti-PEG antibodies: Current situation and countermeasures","volume":"55","author":"Fu","year":"2024","journal-title":"Nano Today"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10107","DOI":"10.1021\/acs.nanolett.1c03946","article-title":"Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv","volume":"21","author":"Tang","year":"2021","journal-title":"Nano Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: A systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.110.177832","article-title":"Fluid Resuscitation with Hemoglobin Vesicles Prevents Growth via Complement Activation in a Hemorrhagic Shock Rat Model","volume":"337","author":"Taguchi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2013.01.012","article-title":"Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan","volume":"443","author":"Li","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Thi, T.T.H., Pilkington, E.H., Nguyen, D.H., Lee, J.S., Park, K.D., and Truong, N.P. (2020). The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation. Polymers, 12.","DOI":"10.3390\/polym12020298"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jconrel.2012.02.025","article-title":"Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor","volume":"159","author":"Mero","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1749-6632.1987.tb45752.x","article-title":"New Acrylic Polymers for Surface Modification of Enzymes of Therapeutic Interest and for Enzyme Immobilization","volume":"501","author":"Veronese","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/088391159300800202","article-title":"Evaluation of Poly(Vinyl Alcohol) for Protein Tailoring-Improvements in Pharmacokinetic Properties of Superoxide-Dismutase","volume":"8","author":"Kojima","year":"1993","journal-title":"J. Bioact. Compat. Polym."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Shin, K., Suh, H.W., Grundler, J., Lynn, A.Y., Pothupitiya, J.U., Moscato, Z.M., Reschke, M., Bracaglia, L.G., Piotrowski-Daspit, A.S., and Saltzman, W.M. (2022). Polyglycerol and Poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces. Biomaterials, 287.","DOI":"10.1016\/j.biomaterials.2022.121676"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bbamem.2006.12.005","article-title":"Pharmacokinetics of poly(hydroxyethyl-L-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration","volume":"1768","author":"Romberg","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1021\/bm100754e","article-title":"Evasion of the Accelerated Blood Clearance Phenomenon by Coating of Nanoparticles with Various Hydrophilic Polymers","volume":"11","author":"Ishihara","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref_72","first-page":"12345","article-title":"Passive Macromolecular Translocation Mechanism through Lipid Membranes","volume":"144","author":"Ekaterina","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/8\/1074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:31:29Z","timestamp":1760034689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/8\/1074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["pharmaceutics17081074"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17081074","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}